Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug
Source: Fortune ·
CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.
From the source
Cellular Intelligence is trying to build an AI model that can predict and eventually control how living cells behave, the same way AI models predict text or images, in hopes of making new medicines faster and cheaper to develop. The company took a step toward that goal Monday, announcing that Moderna co-founder Robert “Bob” Langer and Turing Award-winning AI researcher Yann LeCun have joined its scientific advisory board, along with Jens Nielsen, chief executive of the Novo Nordisk Foundation’s BioInnovation Institute, and Fabian Theis, a computational biologist who directs the Computational Health Center at Helmholtz Munich. Langer is also joining the company’s board of directors as an observer. For decades, developing new medicines, especially cell therapies that use living cells rather than chemical compounds, has depended on slow, expensive trial-and-error lab work. The Boston-based Cellular Intelligence (CI) is trying to apply the same kind of pattern-recognition that powers…